Vor Bio启动1亿美元普通股发行计划

波士顿 - Vor Biopharma Inc. (NASDAQ:VOR) 周一宣布已开始进行1亿美元普通股的承销公开发行。这家临床阶段生物技术公司还计划授予承销商30天期权，可额外购买价值1500万美元的股票。根据 InvestingPro 数据显示，该公司目前市值仅为1.2954亿美元，此次发行对公司而言是一次重大融资，尽管其资产负债表上"现金消耗迅速"，但仍持有比债务更多的现金。

Vor Biopharma股价因1亿美元公开发行计划暴跌

Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) 股价在周一盘后交易中暴跌14.9%，此前这家临床阶段生物技术公司宣布计划公开发行1亿美元的普通股。 这家自身免疫疾病治疗开发商表示，计划发行价值1亿美元的普通股，并为承销商提供30天的额外选择权，可以按公开发行价格减去承销折价和佣金购买最多1500万美元的额外股份。拟议发行的所有股份将由Vor ...

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA ...

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

J.P. Morgan, Jefferies, Citigroup and TD Cowen are acting as joint book-running managers for the proposed offering.
Business Insider

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary ...

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a ...

Vor Biopharma slumps 26%, prices $100M equity at $10 per share

Clinical-stage biotechnology company Vor Biopharma (VOR) priced an underwritten public offering of 10M shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million.
Fintel on MSN

HC Wainwright & Co. Maintains Vor Biopharma (VOR) Buy Recommendation

Fintel reports that on November 14, 2025, HC Wainwright & Co. maintained coverage of Vor Biopharma (NasdaqGS:VOR) with a Buy recommendation. Analyst Price Forecast Suggests 373.07% Upside As of ...